VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA) has taken a significant step forward in its lead BiTAC® T-cell engager program by initiating cell line development, moving the oncology candidate closer to clinical trials. The company announced it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology. This collaboration is intended to support manufacturing, analytical development, and nonclinical studies required before the candidate can enter IND/CTA-enabling studies.

The BiTAC® platform, designed to improve the selectivity of T-cell engagers, aims to reduce toxicity associated with conventional approaches. According to VERAXA, the partnership with ATUM represents an important development milestone as the company prepares its most advanced oncology candidate for future clinical development. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

This advancement comes amid growing interest in T-cell engager therapies, which harness the immune system to target cancer cells. By potentially reducing off-target effects, VERAXA’s BiTAC® technology could offer a safer alternative for patients. The company’s focus on cell line development is a critical step in ensuring consistent and scalable production of the therapeutic candidate.

For more information, the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. These statements are based on information available as of the date hereof, and the company undertakes no duty to update them unless required by law.

The implications of this announcement are twofold: it signals progress in VERAXA’s pipeline and underscores the potential of its BiTAC® platform to address limitations in current cancer immunotherapies. As the company moves toward clinical trials, investors and the medical community will be watching closely for further developments.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program with Cell Line Development Partnership.

The post VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program with Cell Line Development Partnership appeared first on citybuzz.